HIV tropism status needed to initiate therapy with Pfizer's recently
approved Selzentry(TM) (Maraviroc), CCR5 antagonist
MALIBU, Calif., Nov. 15 /PRNewswire/ -- Pathway Diagnostics announces that the U.S. Patent & Trademark Office (USPTO) has issued U.S. Patent number 7,294,458 (the '458 patent) entitled "Analysis of HIV-1 Co-receptor Use in the Clinical Care of HIV-1-Infected Patients." Pathway Diagnostics has licensed the '458 patent (with rights to sub-license) from Health Research Incorporated (HRI), Rensselaer, NY for use in the fields of laboratory diagnosis and monitoring. The '458 patent discloses and claims diagnostic methods for monitoring CCR5 and CXCR4 co-receptor use in the treatment of human immunodeficiency virus (HIV) infection. The '458 patent also claims monitoring CXCR4-specific strain suppression in HIV-positive individuals undergoing highly active anti-retroviral therapy (HAART). Pathway has also obtained licensing rights from HRI for related patent applications, that together with the '458 patent, form the technical foundation of Pathway's SensiTrop HIV tropism assay.
"The patented technology underlying Pathway's SensiTrop assay is a significant innovation that enables HIV treating physicians to select the appropriate treatment for patients using a proprietary molecular assay that is fast and affordable. Pathway's partners have recognized the strength of Pathway's patent portfolio and the importance of these patents when testing CCR5 and CXCR4 co-receptor use for HIV therapy," stated Walter Narajowski, CEO of Pathway Diagnostics.
About HIV Co-receptor tropism and the SensiTrop(TM) assay
The ability of the HIV virus to infect different cell types utilizing
different cell surface receptors is referred to as HIV co-receptor tropism.
One type of HIV that utilizes the CCR5 co-receptor has been shown to be
blocked by CCR5 antagonist drugs such as Selzentry. A different type of HIV
that utilizes the CXCR4
|SOURCE Pathway Diagnostics|
Copyright©2007 PR Newswire.
All rights reserved